1704 completed. 1704 Phase 2, 335 Phase 1, 33 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1704 | Completed 1704 |
| Phase 1 | 335 | Completed 335 |
| Phase 3 | 33 | Completed 33 |
Follow Thoracic Neoplasms: new trials by email Literature Review of Thoracic Neoplasms trials Research Report on Thoracic Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer JS004, Toripalimab, Etoposide - Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent | Phase 2 | Completed | Shanghai Pulmonary Hospital, Shanghai, China | 100 | 2024-11-18 | 2026-10-15 |
| A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for SCLC ivonescimab, irinotecan liposome - Small-cell Lung Cancer | Phase 2 | Completed | Zhejiang Cancer Hospital | 60 | 2024-10-16 | 2026-08-27 |
| A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer Amivantamab, Docetaxel - Carcinoma, Non-Small-Cell Lung | Phase 1 / Phase 2 | Completed | Janssen Research & Development, LLC | 12 | 2024-07-23 | 2026-07-31 |
| Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Metastasis PD-1/PD-L1 inhibitor plus chemotherapy, SRT/WBRT - NSCLC Stage IV | Phase 2 | Completed | Fudan University | 40 | 2024-07-01 | 2026-09-14 |
| Evaluation of Canakinumab in High-Risk Former-Smokers Biospecimen Collection, Bronchoscopy, Canakinumab - Cigarette Smoking-Related Carcinoma, Lung Carcinoma | Phase 2 | Completed | Peter Shields | 41 | 2024-03-11 | 2026-07-07 |
| A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors IMM-6-415 - Advanced Solid Tumor (Phase 1), Pancreas Adenocarcinoma | Phase 1 / Phase 2 | Completed | Immuneering Corporation | 30 | 2024-02-27 | 2025-05-28 |
| Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung Cancer Bojungikki-tang(BJIKT), Pembrolizumab - Non-small Cell Lung Cancer | Phase 2 | Completed | Korea Institute of Oriental Medicine | 26 | 2024-02-08 | 2026-08-05 |
| Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT Anlotinib - Locally Advanced Non-Small Cell Lung Cancer, Thoracic Radiotherapy | Phase 2 | Completed | JIANYANG WANG | 44 | 2024-01-01 | 2026-10-07 |
| A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer Gimistotug, Docetaxel, BGB-15025 - Non-Small Cell Lung Cancer | Phase 2 | Completed | BeiGene | 35 | 2023-10-23 | 2026-01-05 |
| Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung. VGT-309 - Lung Cancer, Lung Metastases | Phase 2 | Completed | Vergent Bioscience, Inc. | 89 | 2023-10-05 | 2026-05-13 |
| Diagnostic Accuracy Study for OWL-EVO1 as a Lung Cancer EVOC® Probe (Evolution Phase 2) OWL-EVO1 - Lung Cancer | Phase 2 | Completed | Owlstone Ltd | 187 | 2023-10-05 | 2026-07-09 |
| Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) M1774, Cemiplimab - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 61 | 2023-09-13 | 2026-09-14 |
| Perioperative Music Therapy Plus Oxycodone in Perioperative Management of Lung Surgery Perioperative Music Therapy - Analgesia, Lung Cancer | Phase 2 | Completed | Hao Long | 66 | 2023-08-01 | 2024-07-17 |
| The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC definitive radiotherapy, induction chemo-immunotherapy, concurrent chemotherapy - Non-small Cell Lung Cancer | Phase 2 | Completed | Sun Yat-sen University | 114 | 2023-07-25 | 2026-08-03 |
| A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) DZD9008+AZD4205 - Non-small Cell Lung Cancer | Phase 2 | Completed | Dizal Pharmaceuticals | 30 | 2023-06-01 | 2026-10-22 |
| A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors SNS-101 (anti-VISTA), Cemiplimab - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 / Phase 2 | Completed | Sensei Biotherapeutics, Inc. | 98 | 2023-05-31 | 2026-09-02 |
| Study to Evaluate the Safety and Efficacy of Serplulimab Plus Bevacizumab and Chemotherapy in NSCLC Patients With Brain Metastases Serplulimab combined with bevacizumab and first-line chemotherapy - Non-small Cell Lung Cancer Stage II, Bevacizumab | Phase 2 / Phase 3 | Completed | Sun Yat-sen University | 40 | 2023-05-14 | 2024-11-13 |
| Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib Lazertinib/Pemetrexed/Carboplatin - Non-small Cell Lung Cancer | Phase 2 | Completed | Yonsei University | 65 | 2023-04-07 | 2026-10-07 |
| Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma Gemcitabine, supportive care - Malignant Pleural Mesothelioma | Phase 2 | Completed | Ain Shams University | 40 | 2023-04-01 | 2024-08-27 |
| Pifenidone Prophylactic Therapy for Radiation Lung Injury in Patients Who Have Previously Received Immune Checkpoint Inhibitors Pirfenidone - Lung Cancer | Phase 2 | Completed | Hubei Cancer Hospital | 41 | 2023-03-31 | 2026-09-18 |
Showing 20 of 1704. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (1193) · Lung Neoplasms (657) · Small Cell Lung Carcinoma (200) · Adenocarcinoma of Lung (100) · Neoplasms (93) · Mesothelioma, Malignant (81) · Breast Neoplasms (75) · Neoplasm Metastasis (61) · Melanoma (57) · Colorectal Neoplasms (49) · Ovarian Neoplasms (48) · Pancreatic Neoplasms (47) · Adenocarcinoma, Bronchiolo-Alveolar (46) · Head and Neck Neoplasms (39) · Brain Neoplasms (37)
Neoplasms by Site (1698) · Respiratory Tract Neoplasms (1673) · Respiratory Tract Diseases (1660) · Lung Diseases (1647) · Neoplasms (1611) · Bronchial Neoplasms (1347) · Carcinoma, Bronchogenic (1346) · Lung Neoplasms (1015) · Neoplasms by Histologic Type (408) · Neoplasms, Glandular and Epithelial (345) · Carcinoma (230) · Adenocarcinoma (156) · Skin and Connective Tissue Diseases (126) · Skin Diseases (125)
Carboplatin (259) · Cisplatin (198) · Paclitaxel (177) · Pemetrexed (159) · Docetaxel (142) · Gemcitabine (138) · Erlotinib Hydrochloride (132) · Bevacizumab (100) · Radiotherapy (94) · pembrolizumab (79) · Nivolumab (63) · Etoposide (55) · Gefitinib (49) · Cetuximab (45) · Vinorelbine (39)
National Cancer Institute (NCI) (95) · Eli Lilly and Company (77) · Memorial Sloan Kettering Cancer Center (43) · Alliance for Clinical Trials in Oncology (39) · M.D. Anderson Cancer Center (35) · SCRI Development Innovations, LLC (31) · Pfizer (30) · Novartis Pharmaceuticals (26) · Hoffmann-La Roche (22) · SWOG Cancer Research Network (21) · AstraZeneca (20) · Bristol-Myers Squibb (19) · Sun Yat-sen University (17) · Amgen (16) · Intergroupe Francophone de Cancerologie Thoracique (16)
United States (1024) · Canada (181) · Spain (177) · France (174) · China (171) · Italy (158) · South Korea (150) · Germany (145) · United Kingdom (120) · Netherlands (91) · Belgium (86) · Poland (81) · Taiwan (81) · Australia (76) · Japan (51)
Afshin Dowlati, MD (8) · David R. Spigel, MD (8) · Shirish M. Gadgeel, MD (6)
PMID 22586319, PMID 23442309, PMID 26291023, PMID 25490004, PMID 27130468, PMID 33241650, PMID 34405547, PMID 34408488, PMID 22473314, PMID 25175099, PMID 27863201, PMID 27959700, PMID 28408243, PMID 28489488, PMID 29293889, PMID 29748847, PMID 29768119, PMID 30267838, PMID 30512189, PMID 31345012, PMID 31576173, PMID 31706099, PMID 33096027, PMID 33595690, PMID 34589918, PMID 34761878, PMID 34870327, PMID 35962934, PMID 37279993, PMID 37934000, PMID 39113428, PMID 40311309, PMID 42686329, PMID 42820295, PMID 10500494, PMID 11165136, PMID 11241082, PMID 12056703, PMID 12565988, PMID 12581572, PMID 12631594, PMID 12721251, PMID 12763216, PMID 12796370, PMID 12871785, PMID 14505160, PMID 14528068, PMID 14722038, PMID 14981103, PMID 14998842
U10CA031946 (31), 2016 (24), U10CA032102 (22), 2014 (16), 2017 (13), 2008 (12), 2018 (12), 2015 (11), P30CA022453 (11), U10CA021115 (11), 2009 (9), N01CM62209 (9), 2019 (8), P30CA006973 (7), P30CA043703 (7)